Literature DB >> 12670740

The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones.

Peter Arner1.   

Abstract

Globally, the prevalence of obesity is escalating, and insulin resistance resulting from increased (predominantly visceral) adipose tissue mass has been identified as a key factor that could drive parallel rises in type 2 diabetes mellitus (T2DM) prevalence. Correlations between these global epidemics have encouraged investigation into potential molecular links between the related impairments in lipid and glucose homeostasis. This article reviews factors released from adipose tissue that could contribute to the development of insulin resistance and beta-cell dysfunction, including tumour necrosis factor alpha (TNF-alpha), free fatty acids (FFAs), adiponectin, resistin and leptin. It also considers whether agonists of the peroxisome proliferator-activated receptor gamma, which is abundant in adipose tissue, might have an important impact on factors associated with adipocyte metabolism. For example, the thiazolidinediones, a class of oral anti-diabetic agents that reduce insulin resistance and improve beta-cell function, might mediate these effects by regulating adipocyte-derived factors, in particular TNF-alpha and FFAs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670740     DOI: 10.1016/s1043-2760(03)00024-9

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  80 in total

Review 1.  Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport.

Authors:  C Fürnsinn; T M Willson; B Brunmair
Journal:  Diabetologia       Date:  2006-11-22       Impact factor: 10.122

Review 2.  Cytokines and the pathogenesis of non-alcoholic steatohepatitis.

Authors:  A M Diehl; Z P Li; H Z Lin; S Q Yang
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

3.  Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes.

Authors:  Aimee M Powelka; Asha Seth; Joseph V Virbasius; Evangelos Kiskinis; Sarah M Nicoloro; Adilson Guilherme; Xiaoqing Tang; Juerg Straubhaar; Andrew D Cherniack; Malcolm G Parker; Michael P Czech
Journal:  J Clin Invest       Date:  2005-12-22       Impact factor: 14.808

4.  Increased adipocyte S-nitrosylation targets anti-lipolytic action of insulin: relevance to adipose tissue dysfunction in obesity.

Authors:  Hilla Ovadia; Yulia Haim; Ori Nov; Orna Almog; Julia Kovsan; Nava Bashan; Moran Benhar; Assaf Rudich
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

5.  Identification and validation of novel adipokines released from primary human adipocytes.

Authors:  Stefan Lehr; Sonja Hartwig; Daniela Lamers; Susanne Famulla; Stefan Müller; Franz-Georg Hanisch; Claude Cuvelier; Johannes Ruige; Kristin Eckardt; D Margriet Ouwens; Henrike Sell; Juergen Eckel
Journal:  Mol Cell Proteomics       Date:  2011-09-26       Impact factor: 5.911

6.  Crocetin attenuates palmitate-induced insulin insensitivity and disordered tumor necrosis factor-alpha and adiponectin expression in rat adipocytes.

Authors:  L Xi; Z Qian; G Xu; C Zhou; S Sun
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

Review 7.  Diabetes mellitus and inflammation.

Authors:  Eric Lontchi-Yimagou; Eugene Sobngwi; Tandi E Matsha; Andre Pascal Kengne
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 8.  Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review.

Authors:  John N Fain
Journal:  Mediators Inflamm       Date:  2010-05-23       Impact factor: 4.711

9.  Role of Receptor-Interacting Protein 140 in human fat cells.

Authors:  Niklas Mejhert; Jurga Laurencikiene; Amanda T Pettersson; Maria Kaaman; Britta M Stenson; Mikael Rydén; Ingrid Dahlman
Journal:  BMC Endocr Disord       Date:  2010-01-29       Impact factor: 2.763

10.  Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells.

Authors:  Henrike Sell; Jurga Laurencikiene; Annika Taube; Kristin Eckardt; Andrea Cramer; Angelika Horrighs; Peter Arner; Jürgen Eckel
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.